Estrogen and progesterone receptors in breast cancer
- 1 November 2014
- journal article
- review article
- Published by Future Medicine Ltd in Future Oncology
- Vol. 10 (14), 2293-2301
- https://doi.org/10.2217/fon.14.110
Abstract
Breast cancer is the most common cancer in women worldwide. The majority of breast cancers show overexpression of estrogen receptors (ERs) and progesterone receptors (PRs). The development of drugs to target these hormone receptors, such as tamoxifen, has brought about significant improvement in survival for women with hormone receptor-positive breast cancers. Since information about ER and PR is vital for patient management, quality assurance is important to ensure accurate testing. In recent guidelines, the recommended definition of ER and PR positivity is 1% or more of cells that stain positive. Semiquantitative assessment of ER and PR is important for prognosis and, hence, management. Even with the development of genomic tests, hormone receptor status remains the most significant predictive and prognostic biomarker.Keywords
This publication has 51 references indexed in Scilit:
- Factors affecting estrogen receptor status in a multiracial Asian country: An analysis of 3557 casesThe Breast, 2011
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patientsBreast Cancer Research, 2007
- Mechanisms of Estrogen Receptor Signaling: Convergence of Genomic and Nongenomic Actions on Target GenesMolecular Endocrinology, 2005
- Ethnicity and Breast Cancer: Factors Influencing Differences in Incidence and OutcomeJNCI Journal of the National Cancer Institute, 2005
- Risk Factors for Breast Cancer According to Estrogen and Progesterone Receptor StatusJNCI Journal of the National Cancer Institute, 2004
- Rates for Breast Cancer Characteristics by Estrogen and Progesterone Receptor Status in the Major Racial/Ethnic GroupsBreast Cancer Research and Treatment, 2002
- Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screeningJournal of Clinical Pathology, 2000
- Treatment of Primary Breast Cancer with Chemotherapy and TamoxifenThe New England Journal of Medicine, 1981
- ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.1The Lancet, 1896